Ultibro Breezhaler
Аналоги Ultibro Breezhaler
Знайдіть доступніші аналоги та дженерики для Ultibro Breezhaler.
Активний інгредієнт: indacaterol;glycopyrronium bromide
Опис товару
About Ultibro Breezhaler
Ultibro Breezhaler is a medicine that contains two active substances, indacaterol (85 micrograms) and glycopyrronium (43 micrograms).
What it is used for
Ultibro Breezhaler is used as maintenance (regular) treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing air in and out of the lungs.
How it is used
Ultibro Breezhaler is available as capsules containing a powder for inhalation and can only be obtained with a prescription. The recommended dose is one inhalation once a day of the powder content of a single capsule. It is taken at the same time each day using the Ultibro Breezhaler device. The contents of the capsules must not be inhaled using any other device. In patients with severely reduced kidney function Ultibro Breezhaler should only be used after a careful benefit-risk assessment.
How it works
The active substances in Ultibro Breezhaler, indacaterol and glycopyrronium, work in different ways to widen the airways and improve breathing in COPD. Indacaterol is a long-acting beta-2 agonist. It works by attaching to beta-2-adrenergic receptors found in the muscles of many organs including the airways of the lungs. When inhaled, indacaterol reaches the receptors in the airways and activates them. This causes the muscles of the airways to relax. Glycopyrronium is a muscarinic-receptor antagonist. It works by blocking some receptors called muscarinic receptors, which control the contraction of muscles. When glycopyrronium is inhaled, it causes the muscles of the airways to relax. The combined action of the two active substances helps to keep the airways open and allows the patient to breathe more easily. Muscarinic receptor antagonists and long-acting beta-2-adrenergic agonists are commonly combined in the management of COPD.
Active substance: indacaterol (85 micrograms) and glycopyrronium (43 micrograms)
Оцінки відвідувачів
Допоможіть іншим — оцініть корисність цієї сторінки.
Оцінок ще немає — будьте першим.
